Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $52.11

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $52.11.

MIRM has been the subject of several recent research reports. JMP Securities upped their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, March 14th. HC Wainwright restated a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Raymond James lowered their price target on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a research report on Tuesday, December 19th. SVB Leerink lowered their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Monday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th.

Insider Activity at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was purchased at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the transaction, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt acquired 2,000 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, March 27th. The stock was bought at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the transaction, the chief financial officer now owns 14,000 shares in the company, valued at approximately $347,200. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. 24.06% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. Frazier Life Sciences Management L.P. lifted its stake in Mirum Pharmaceuticals by 0.4% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 6,495,392 shares of the company’s stock valued at $191,744,000 after buying an additional 25,000 shares in the last quarter. Eventide Asset Management LLC lifted its stake in Mirum Pharmaceuticals by 14.4% during the third quarter. Eventide Asset Management LLC now owns 3,958,579 shares of the company’s stock valued at $125,091,000 after buying an additional 499,378 shares in the last quarter. Vanguard Group Inc. lifted its stake in Mirum Pharmaceuticals by 46.2% during the fourth quarter. Vanguard Group Inc. now owns 2,476,244 shares of the company’s stock valued at $73,099,000 after buying an additional 782,901 shares in the last quarter. BlackRock Inc. lifted its stake in Mirum Pharmaceuticals by 18.7% during the second quarter. BlackRock Inc. now owns 2,030,375 shares of the company’s stock valued at $52,526,000 after buying an additional 320,549 shares in the last quarter. Finally, Cadian Capital Management LP lifted its stake in Mirum Pharmaceuticals by 34.8% during the fourth quarter. Cadian Capital Management LP now owns 1,934,922 shares of the company’s stock valued at $57,119,000 after buying an additional 500,000 shares in the last quarter.

Mirum Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ:MIRM opened at $23.91 on Tuesday. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.02 and a beta of 1.14. Mirum Pharmaceuticals has a 1-year low of $23.76 and a 1-year high of $35.56. The company’s fifty day moving average is $27.16 and its two-hundred day moving average is $28.65. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. Equities analysts anticipate that Mirum Pharmaceuticals will post -1.12 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.